1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride:Exports & Compliance White Paper 2026

I. Executive Summary

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC hydrochloride, CAS 25952-53-8; C8H17N3·HCl, molecular weight 191.71) is the water-soluble workhorse of carbodiimide coupling chemistry. Unlike dicyclohexylcarbodiimide, whose urea by-product is insoluble and difficult to purge in aqueous systems, EDC generates a water-soluble urea that washes out with a simple aqueous work-up, which is why it has become the default activating agent for peptide amide formation, for two-step NHS-ester bioconjugation and for the functionalisation of carboxylated surfaces, nanoparticles and polysaccharides. Demand in 2026 is being pulled by industrial-scale peptide API campaigns, antibody-drug-conjugate and oligonucleotide manufacture, and by the growth of injectable biomaterials.

The commercial risk in this molecule is not synthesis but decay. EDC hydrochloride is strongly hygroscopic and thermally labile: it hydrolyses to the corresponding urea, 1-ethyl-3-(3-dimethylaminopropyl)urea, on contact with moisture, and it rearranges and darkens on warm storage. A lot can look correct on appearance and still deliver half the expected conversion. Serious buyers therefore specify assay by titration or HPLC, Karl Fischer water, urea content, residual solvent profile and colour, and they buy material that has been aliquoted, nitrogen-packed and shipped cold.

Commercially, the market has split into a research-grade tier competing on catalogue price and a GMP-adjacent tier competing on documentation: ICH Q7-aligned manufacture and change control, ICH M7 assessment of residual reactive reagent, ICH Q3C solvent and Q3D elemental-impurity data, TSE/BSE and endotoxin statements, and EXCiPACT-equivalent supplier qualification. At the same time, T3P, COMU, DIC with Oxyma-type additives and catalytic direct amidation are displacing EDC in specific scale-up contexts, so the defensible position in 2026 is a stability-documented, application-supported product rather than a commodity reagent.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

EDC hydrochloride is a white to off-white crystalline solid supplied as the hydrochloride salt precisely because the free carbodiimide base is unstable: the salt is handleable, water-soluble and methanol-soluble, and it releases the reactive N=C=N function under the reaction conditions. Its reactivity follows the classic carbodiimide pathway: attack of the carboxylate on the central carbon of the protonated carbodiimide gives an O-acylisourea, which is then intercepted by an amine, an alcohol or a stabilising additive.

• O-Acylisourea activation and N-acylurea rearrangement: The O-acylisourea is the productive intermediate: nucleophilic attack by an amine gives the amide and liberates the water-soluble urea, while attack by an alcohol gives the ester. Competing with it are two loss channels — intramolecular rearrangement to a stable N-acylurea, which consumes both acid and reagent irreversibly, and hydrolysis back to the starting carboxylic acid. Additives exist to interrupt exactly these two channels.
• pH window and the two-step NHS/sulfo-NHS protocol: Carbodiimide activation is fastest under mildly acidic conditions, roughly pH 3.5 to 5, whereas amine coupling is most efficient nearer neutrality. The industrial compromise is a two-step protocol: EDC plus N-hydroxysuccinimide or its sulfonated analogue first form a relatively stable, amine-reactive ester, then coupling is run at pH 7 to 8, giving the zero-length amide linkage used in protein crosslinking and surface immobilisation.

2.2 Synthesis and Manufacturing Technologies

Carbodiimides are made by dehydration. At process level, EDC manufacture is a three-stage sequence: construct the unsymmetrical substituted urea, dehydrate it to the carbodiimide, and isolate the hydrochloride as a stable, handleable salt. Each stage has a distinct impurity signature that the analytical specification must resolve.

• Urea construction by isocyanate and amine addition: N,N-Dimethylaminopropane-1,3-diamine is reacted with ethyl isocyanate, or with an isothiocyanate intermediate of equivalent reactivity, to give the unsymmetrical urea 1-ethyl-3-(3-dimethylaminopropyl)urea. Reaction control matters because the diamine presents two nitrogen centres of different reactivity: over-addition and wrong-regiochemistry give bis-urea and guanidine-type by-products that survive into the final salt.
• Dehydration and hydrochloride salt isolation: The urea is dehydrated with a halogenating or sulfonylating dehydrating agent — tosyl chloride with base, phosphorus oxychloride, thionyl chloride or phosphorus pentoxide — to the free carbodiimide, which is converted to the hydrochloride with anhydrous hydrogen chloride in a dry solvent. Because the free base is thermally labile, dehydration and salt formation are run cold, and the salt is crystallised, washed with dry solvent and dried under vacuum at low temperature.

2.3 Core Application Matrix

• Amide and ester bond formation in peptide synthesis: The largest single use. EDC mediates solution-phase and solid-phase amide couplings, segment condensations and macrolactamisations, and with an alcohol nucleophile it delivers esters and lactones. It is favoured where an aqueous or aqueous-organic work-up is required to purge the urea, and where a chloride-free, metal-free reagent is specified.
• Bioconjugation, protein crosslinking and NHS-ester systems: Combined with NHS or sulfo-NHS, EDC is the standard zero-length crosslinker for attaching amines to carboxyls: protein-protein conjugation, antibody-enzyme and antibody-drug conjugate assembly, immobilisation of proteins and peptides onto carboxylated beads, chips, sensors and chromatography media, and activation of carboxylated nanoparticles.
• Oligonucleotides, polysaccharides and materials functionalisation: EDC activates phosphate and carboxyl functions in oligonucleotide ligation and labelling, crosslinks hyaluronic acid, alginate, gelatin and collagen into implantable hydrogels and haemostatic matrices, and grafts functionality onto carboxylated polymers, cellulose and carbon surfaces for diagnostics and advanced materials.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Three demand engines define 2026. The first is industrial-scale peptide API: multi-tonne peptide campaigns have moved from kilo-lab to dedicated plants, and every kilogram of peptide consumes several kilograms of coupling reagent, pulling EDC from catalogue volumes into contract volumes. The second is bioconjugation: antibody-drug conjugates, oligonucleotide conjugates, diagnostic reagents and vaccine carriers all rely on water-compatible activation. The third is biomaterials — injectable and implantable hydrogels, haemostats and resorbable matrices — where EDC-crosslinked collagen and hyaluronic acid are established industrial platforms.

3.2 Capacity Distribution and Export Flows

Reagent and intermediate capacity is concentrated in China, particularly around the peptide-reagent clusters of Jiangsu, Zhejiang, Shanghai and Sichuan, which supply both domestic peptide CDMOs and export customers in Europe, North America and India. European and North American supply is anchored in Germany, Switzerland and the United States through specialist reagent producers and large catalogue houses that hold inventory, perform secondary qualification and ship cold regionally. Indian producers and CDMOs, clustered around Hyderabad and Bengaluru, supply domestic peptide and generic API manufacturers and increasingly export qualified reagent grades.

3.3 Market Bifurcation and Pricing Dynamics

The market is sharply bifurcated. Research-grade material, sold in 5 to 100 g bottles with a nominal assay of 98 percent or higher and no cold-chain guarantee, competes almost purely on catalogue price and is effectively a commodity. GMP-adjacent material, sold in kilogram quantities with full impurity profiles, residual-solvent and elemental-impurity data, change-control commitments and temperature-logger-verified cold chain, commands a substantial premium that customers accept because a failed coupling campaign costs far more than the reagent. Pricing tracks the diamine and isocyanate raw-material basket, solvent cost and cold-chain logistics; substitution pressure from T3P, COMU and DIC-plus-Oxyma systems caps the achievable premium.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

EDC hydrochloride is a reagent rather than an active substance, but because it is consumed in GMP synthesis and in the manufacture of injectable and implantable products, it is audited as though it were one. The regulatory burden therefore falls on classification and labelling, on impurity science, and on the supplier's ability to demonstrate control over change.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and CLP hazard classification: EDC hydrochloride is registered under REACH for its manufactured and imported tonnage, and must be supplied with a CLP-aligned safety data sheet in the buyer's language. Notified classifications centre on skin corrosion or irritation, serious eye damage or eye irritation and skin sensitisation, with acute oral toxicity in category 4 commonly notified, which drives PPE requirements, containment decisions and occupational exposure banding at the user's site.
• ICH Q7, Q11 and medical-device interfaces: European customers running GMP campaigns expect reagent suppliers to operate an ICH Q7-aligned quality system, to justify the reagent as a starting material or process aid under ICH Q11, and to provide TSE/BSE-free and endotoxin statements where the output is parenteral. Where EDC-crosslinked material becomes a device, ISO 10993 biological evaluation and EU MDR technical documentation extend the audit back to the reagent lot.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory status and FDA-facing documentation: EDC hydrochloride is listed on the TSCA Inventory and active for commercial purposes, with Chemical Data Reporting obligations where thresholds are met. For regulated drug manufacture, users expect a supplier package supporting an FDA drug master file or equivalent: route description, impurity profile, specifications and a change-control commitment, so that the reagent does not become an uncontrolled variable in the filing.
• ICH M7, Q3C and Q3D impurity control: Carbodiimides are reactive, electrophilic species, so residual EDC and its dehydration by-products are assessed under ICH M7 with purge-factor reasoning documented under ICH Q11 and M7 Option 4 rather than by default specification. In parallel, buyers require ICH Q3C residual-solvent statements for the crystallisation solvents, ICH Q3D elemental-impurity data, and nitrosamine risk screening on the amine raw-material chain.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

For a reagent used in stoichiometric quantity, the environmental burden is process mass rather than hazard. Carbodiimide couplings generate a full equivalent of urea by-product, consume dehydrating agents in manufacture, and require halogenated or polar aprotic solvents — all of which register in the user's process mass intensity and in the solvent-recovery and waste-treatment costs of the campaign.

5.1 Carbon Footprint and Circular Economy

Two factors dominate the footprint. The first is the cold chain: maintaining minus 20 °C storage and frozen transport for a hygroscopic, thermally labile reagent is itself a Scope 1 and Scope 3 emission that buyers are starting to question, which is why room-temperature-stable formulations and improved packaging are active development themes. The second is the coupling chemistry itself: solvent-intensive coupling and purification, and the disposal of urea-containing aqueous waste, have made carbodiimide reagents a recurring subject in pharmaceutical green-chemistry reagent guides, driving interest in T3P, COMU and catalytic direct amidation as lower-process-mass alternatives.

5.2 Sustainable Sourcing and Traceability

Traceability for a GMP-adjacent reagent means lot-level identity and integrity: certificate of origin, analytical fingerprint retained per lot, tamper-evident seals, and documented chain of custody from the producing plant through any repacker or distributor. Because mislabelled or diluted reagent is a recurring failure mode in this category, qualified buyers audit the physical supply chain, require ISO 9001 or EXCiPACT-equivalent supplier certification, ISO 14001 environmental management, and animal-origin-free declarations, and they re-assay on receipt rather than trusting the supplier's certificate alone.

VI. Supply Chain Resilience and Export Logistics

EDC hydrochloride is a cold-chain, moisture-critical product. It is not sensitive to oxygen to the same degree as a phosphine or an organometallic, but it is sensitive to water and heat, and both act silently: a single warm weekend in a warehouse can convert several percent of the lot to urea. Logistics design is therefore an integral part of product quality, not a service layer around it.

6.1 Packaging Standards and Moisture/Contamination Control

• Cold chain, desiccant and moisture barrier: Fill into amber glass or high-density polyethylene bottles with PTFE-lined closures, under a dry nitrogen headspace, with a desiccant sachet and a heat-sealed moisture-barrier pouch inside the outer carton. Ship at minus 20 °C with gel packs or dry ice and a temperature data logger, and specify the excursion limit in the supply agreement.
• Aliquoting, retest and shelf-life management: Supply pre-weighed aliquots packed under inert gas so that a production campaign opens one container at a time, and avoid repeated warm-cool cycles at the customer's site. Define a retest period, typically 12 to 24 months at minus 20 °C, and quarantine and re-assay incoming lots for assay and water before release to manufacturing.

6.2 Dangerous Goods Identification and Transit Protocols

Where the notified classification is limited to irritation and sensitisation, EDC hydrochloride is normally shipped as a non-dangerous good, but any notification carrying skin corrosion requires Class 8 documentation, typically UN 3261 for a corrosive acidic organic solid, with UN-certified packaging and GHS labelling. Dry ice used as refrigerant is itself regulated: UN 1845, IATA packing instruction 954 and IMDG equivalents require declared net mass, vented packaging and correct marking. Air freight is preferred for small high-value lots; for bulk kilogram shipments, reefer or temperature-controlled road and sea options are evaluated against the same excursion limits.

VII. Enterprise Global Expansion Strategy Guide

Three moves build durable position in this reagent market, and all three shift the conversation away from price per gram.

1. Sell the stability package, not the bottle: Offer a specification built on Karl Fischer water, urea content and assay rather than on appearance, ship in nitrogen-packed aliquots with temperature-logged cold chain, and publish stability data across the intended storage window so that the customer's incoming release test becomes a formality.
2. Qualify into GMP with a filing-ready package: Provide an impurity profile with identifications, ICH Q3C residual-solvent and Q3D elemental-impurity data, TSE/BSE and endotoxin statements, ICH M7 purge reasoning, and a written change-control commitment, backed by an ICH Q7-auditable quality system and ISO 9001 certification.
3. Position against alternatives with application data: Publish head-to-head comparisons against T3P, COMU, HATU and DIC-plus-Oxyma systems on conversion, by-product load and process mass intensity, and supply EDC with matched NHS or sulfo-NHS and buffer kits. Technical service converts a catalogue reagent into a specified process input.

VIII. Conclusion

EDC hydrochloride enters 2026 with demand pulled by the industrialisation of peptide and conjugate manufacturing and pushed by the expansion of injectable biomaterials. Its technical position — water-soluble, metal-free, and generating a water-soluble urea — remains difficult to replicate in aqueous and bioconjugation contexts, which protects its core franchise even as alternative reagents take share in purely organic, large-scale amide formation.

The value, however, has migrated from the molecule to the file and the cold chain. Suppliers who can document stability, control impurities under ICH M7 and Q3D logic, and guarantee temperature through to the customer's warehouse will be specified into campaigns and defended on renewal; suppliers selling nominal assay in a plain bottle will remain interchangeable and permanently price-exposed.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global EDC hydrochloride (EDC·HCl) Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global EDC hydrochloride (EDC·HCl) supply chain:

• China — peptide reagent and intermediate manufacturing cluster: Producers in Jiangsu, Zhejiang, Shanghai and Sichuan run carbodiimide and coupling-reagent plants at multi-tonne scale, supplying domestic peptide CDMOs and exporting kilogram and tonne quantities with growing GMP documentation capability and established frozen-export logistics.
• Europe — specialty reagent producers and qualifying distributors: German and Swiss reagent specialists and peptide-chemistry houses hold the highest-specification tier, offering aliquoted cold-chain packs, full analytical documentation and technical service into pharmaceutical and biomaterials customers across the EEA and the United Kingdom.
• United States and India — catalogue distribution and CDMO-linked supply: US catalogue and custom-synthesis suppliers fulfil research and clinical-scale demand with regional cold-chain depots, while Indian producers around Hyderabad and Bengaluru supply domestic peptide and generic API manufacturers and increasingly export qualified reagent grades.